Abbott Labs short? Experience report of a type 1 diabetic

At Abbott $ABT (+0,68 %) is currently experiencing problems and the media are not (yet) reporting. One of their most publicized products the Freestyle Libre 3 (rough estimates say 5% of Abbott's sales in the diabetes care division) has been having severe problems for months, which are very dangerous for type 1 diabetics. I myself have been directly affected 4 times in the past 6 months (I need 12 sensors for the period and 4). About the problem: the sensor indicates a permanent hypoglycemia and the blood sugar rises higher and higher and can easily derail if you rely on it and continue to try to eliminate the hypoglycemia. (Children and older people are particularly at risk here because they are unable to recognize the symptoms and react accordingly. It is also very difficult for people who are there to supervise the illness if they are not aware of the problem. ) This is well known in medical practices and is also communicated to patients. Tearing off the sensors and fitting a new one is the only way to bring about an improvement. Abbott themselves will send new sensors if there is a complaint without resistance, but they will not know the problem as the complaint process is weak in querying the reasons. (the category is not stored in the automated query) This means that they are (presumably) not actively working on it. (Problem has existed for 6 months, which is another indicator of this) No idea how private investors can capitalize on this now, but in the USA there is a good chance that the problem will result in lawsuits due to the treatment costs resulting from a derailed blood sugar. I hope you enjoyed this short report and wish you a good weekend!